Hofseth BioCare
Hofseth BioCare ASA is a Norwegian publicly listed specialty ingredients company that upcycles salmon industry side streams into clinically validated bioactive ingredients — OmeGo® omega-3 and ProGo® peptides — for nutraceutical, pharmaceutical, and premium pet nutrition customers globally.
- Company typePublic
- Founded2009
- HeadquartersÅlesund, Norway
- Headcount51–100
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Hofseth BioCare does
Hofseth BioCare ASA is a Norwegian publicly listed specialty ingredients company (Oslo Stock Exchange: HBC) that converts salmon industry side streams into clinically validated bioactive health ingredients. The company's core technology upcycles salmon processing by-products into full spectrum omega-3 (OmeGo®) and salmon-derived bioactive peptides (ProGo®), serving nutraceutical manufacturers, pharmaceutical and cosmetic formulators, and the premium pet nutrition segment through its wholly owned Brilliant Petcare brand. Operations are anchored at the Midsund processing plant in Norway, which recorded its highest ever raw material throughput in 2025, with commercial offices in Oslo, London, Zürich, and Palo Alto supporting a multi-region B2B go-to-market.
The business operates across four revenue streams: direct B2B sales of bioactive ingredients to manufacturers, premium pet nutrition retail through Brilliant Petcare, licensing and supply agreements (notably the May 2026 exclusive ProGo® license to US-based Fission Holdings, which carries a USD 3 million minimum purchase commitment by January 2027 and is projected to exceed USD 5 million annually), and a 52%-owned US biotech subsidiary AecorBio Inc. that is developing lead candidate FT-002a for prostate cancer. Capital structure is supported by recurring equity raises (NOK 141 million in July 2022 and NOK 158 million in October 2025) and a CHF 3.5 million bond placement in May 2025, with proceeds directed toward B2B ingredients scaling, metabolic health and healthy aging product development, and expansion into Asia and the United States. Key shareholders include Guy Urquhart, Hofseth International AS, Aqua-Spark, Yokorei Co. Ltd., and Bonafide Wealth Management. Recent milestones include the April 2026 publication of head-to-head clinical trial data for OmeGo® demonstrating a >70% increase in Omega 3 Index over 14 weeks and 2.5x greater anti-inflammatory efficacy than concentrated fish oil comparators, alongside regulatory approvals in Australia and South Korea.
Hofseth BioCare firmographics
Firmographics- Name
- Hofseth BioCare
- Legal name
- Hofseth BioCare ASA
- Website
- https://hofsethbiocare.com
- Company type
- Public
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Hofseth BioCare ASA is a Norwegian publicly listed specialty ingredients company that upcycles salmon industry side streams into clinically validated bioactive ingredients — OmeGo® omega-3 and ProGo® peptides — for nutraceutical, pharmaceutical, and premium pet nutrition customers globally.
- Ownership category
- akta.pro rank
Hofseth BioCare industry classification
Industry- Product category
- Nutraceutical Ingredients
- NAICS
- Dog and Cat Food Manufacturing (311111), Seafood Product Preparation and Packaging (3117), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Prepared Fresh Or Frozen Fish & Seafoods (2092), Fats & Oils (2070), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Functional & Veterinary Diet Pet Food (CRADAFAF)
- akta.pro secondary industries
- Natural/Organic & Limited-Ingredient Diets (CRADAFAH), Nutraceuticals & Functional Ingredients for Animal Diets (Probiotics, Omega-3, Joint, GI) (HLAMAHAH)
Keywords
Where Hofseth BioCare is headquartered
LocationHeadquarters
- HQ city
- Ålesund
- HQ country
- Norway
- HQ region
- Europe
Offices6 records
Markets served
Hofseth BioCare business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- B2B Ingredients Sales: Sale of salmon-derived bioactive ingredients including OmeGo® omega-3 and ProGo® peptide ingredients to nutraceutical, pharmaceutical, and pet nutrition manufacturers worldwide.
- Premium Pet Nutrition: Brilliant Petcare premium pet nutrition brand generates revenue through sale of finished pet health products targeting the premium pet nutrition market segment.
- Licensing and Supply Agreements: Revenue from exclusive licensing agreements including ProGo® supply to Fission Holdings with minimum purchase commitments of $3 million annually, representing a new global route-to-market.
- Biotech Subsidiary Divestment: Partial divestment of AecorBio Inc. subsidiary at USD 36 million valuation, with HBC retaining 52% ownership while generating USD 5 million from share sale.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels3 records
Hofseth BioCare product offering
Product offeringCore offering
Hofseth BioCare ASA upcycles salmon industry side streams into bioactive health ingredients for human and pet nutrition. Its core offerings are OmeGo® full spectrum omega-3 and ProGo® salmon-derived bioactive peptide ingredients sold B2B to nutraceutical and pet nutrition manufacturers, complemented by the Brilliant Petcare premium pet nutrition brand.
Product overview
Hofseth BioCare ASA is a Norwegian consumer and pet health company that upcycles salmon industry side streams into health ingredients. The company operates a platform of salmon-derived bioactive ingredients spanning human nutrition (ProGo® peptide ingredient, OmeGo® omega-3 product) and premium pet nutrition (Brilliant Petcare brand). The portfolio also includes biotech subsidiary AecorBio Inc. focused on pharmaceutical applications. Operations span Oslo, London, Zürich, and Palo Alto with a processing plant in Midsund, Norway.
Differentiator
Problem solved
Functional benefit
Brands
- OmeGo®: Full spectrum omega-3 product that demonstrated clinical trial results showing increased Omega 3 Index by over 70% after 14 weeks, outperforming concentrated fish oil comparators.
- ProGo®
- Brilliant Petcare
Products and services
- ProGo®
- OmeGo® Full spectrum omega-3 product derived from salmon, clinically proven to increase Omega 3 Index and reduce inflammatory markers linked to cardiovascular, metabolic, and cancer risks.
- Brilliant Petcare
- AecorBio Inc. (FT-002a) US biotech subsidiary focused on pharmaceutical development of FT-002a for prostate cancer treatment; Hofseth BioCare retains approximately 52% ownership after partial divestment.
Quantifiable outcome
- 70%+ increase in Omega 3 Index after 14 weeks with OmeGo® product
- +3 more outcomes
Companies that use Hofseth BioCare
Customer profileSegments4 records
Ideal customer profiles4 records
Hofseth BioCare technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Hofseth BioCare partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- Fission Holdings LLCflagshipExclusive License and Supply Agreement signed May 22, 2026 granting Fission Holdings worldwide rights to market, distribute, and sell HBC's ProGo® salmon-derived bioactive peptide ingredient through affiliate and network marketing channels. Fission is obligated to purchase minimum $3 million of ProGo® by January 31, 2027 to secure exclusivity, with projected annual sales exceeding $5 million.
- Metabolic Elite / Jim LaVallecoreStrategic product partnership to develop performance nutrition products for athletes combining HBC's marine-based ingredients with Metabolic Elite's formulations. Focus areas include recovery, endurance, and metabolic health with emphasis on sustainability and natural resource utilization.
- AecorBio Inc.coreUS-based biotech subsidiary focused on pharmaceutical applications including FT-002a for prostate cancer treatment. HBC divested 1,616,498 shares for USD 5 million at USD 36 million valuation while retaining 52% ownership. Subsidiary shows promising preclinical results.
Scale indicators12 records
Recent moves8 records
Expansion highlights7 records
Hofseth BioCare competitors and assessment
Company assessmentDirect peers
- Aker BioMarine: Norwegian-listed marine ingredient company producing krill-derived omega-3 and protein products for nutraceutical and aquaculture markets. Directly comparable business model of harvesting/processing marine raw materials into premium bioactive ingredients for human and animal nutrition.
- Epax (Pelagia): Leading producer of marine-derived omega-3 EPA/DHA concentrates used in nutraceutical and pharmaceutical applications. Closely comparable as a B2B ingredient supplier focused on purified, high-concentration fish oil derivatives competing with Hofseth's full-spectrum positioning.
- GC Rieber Oils: Norwegian refiner of marine oils producing omega-3 concentrates for supplements and functional food. Comparable as a Nordic marine ingredient manufacturer serving nutraceutical OEMs with value-added fish oil products.
- TripleNine (FF Skagen): Danish producer of fish meal, fish oil, and protein hydrolysates from marine bycatch and side streams. Directly comparable upcycling model converting marine processing residues into protein and oil ingredients for feed and nutrition markets.
- Nordic Naturals: Leading omega-3 supplement brand sourcing marine oils for finished consumer health products. Comparable target customer base and product category (omega-3 supplementation), though positioned downstream as a finished brand rather than B2B ingredient supplier.
Broad incumbents
- DSM-Firmenich: Global nutrition and health ingredients giant with broad omega-3, vitamin, and premix portfolios including marine-sourced ingredients for human and animal nutrition. Comparable as a large incumbent competing in the same ingredient categories HBC addresses.
- BASF Animal Nutrition: Diversified chemical and ingredient manufacturer with omega-3 (including omega-3 from algae and fish) and animal nutrition product lines. Relevant broad incumbent in the nutritional ingredients space where HBC competes.
- Cargill Animal Nutrition: One of the largest global animal nutrition and aqua-feed producers with salmon-feed products through its EWOS business. Comparable as a major incumbent in salmon-adjacent nutrition, particularly relevant for HBC's pet nutrition and aquaculture side-stream strategy.
- BioMar: Major Norwegian-headquartered aquaculture feed manufacturer producing salmon feed with sustainability focus. Comparable upcycling and marine-protein themes, though serving the aquaculture feed segment rather than human nutraceuticals directly.
Emerging players
- Symrise Diana Pet Food: Specialty ingredient division of Symrise providing palatants and functional ingredients for the premium pet food industry. Comparable as a supplier of premium functional ingredients into the pet nutrition value chain that HBC's Brilliant Petcare competes within.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Hofseth BioCare social profiles
Digital presenceHofseth BioCare financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hofseth BioCare leadership team
Management profileNumber of profiles
Profiles2 records
Hofseth BioCare subsidiaries and ownership
Company hierarchySubsidiaries2 records
Hofseth BioCare funding detail
Funding detailFunding overview
Funding rounds6 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hofseth BioCare M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hofseth BioCare
What does Hofseth BioCare do?
Hofseth BioCare ASA upcycles salmon industry side streams into bioactive health ingredients for human and pet nutrition. Its core offerings are OmeGo® full spectrum omega-3 and ProGo® salmon-derived bioactive peptide ingredients sold B2B to nutraceutical and pet nutrition manufacturers, complemented by the Brilliant Petcare premium pet nutrition brand.
Is Hofseth BioCare a public or private company?
Hofseth BioCare is a public company. It is classified as public and is currently operating.
When was Hofseth BioCare founded?
Hofseth BioCare was founded in 2009. It employs 51 to 100 people.
Where is Hofseth BioCare based?
Hofseth BioCare is headquartered in Ålesund, Norway, in the Europe region.
How does Hofseth BioCare make money?
Four revenue lines are on record. B2B Ingredients Sales are the primary driver. The others are premium Pet Nutrition, licensing and Supply Agreements and biotech Subsidiary Divestment.
Who are Hofseth BioCare's main competitors?
Direct peers on record are Aker BioMarine, Epax (Pelagia), GC Rieber Oils, TripleNine (FF Skagen) and Nordic Naturals. Broad incumbents are DSM-Firmenich, BASF Animal Nutrition, Cargill Animal Nutrition and BioMar. Symrise Diana Pet Food is listed as an emerging player.
Does Hofseth BioCare have an API?
No public API is recorded for Hofseth BioCare.
What industry is Hofseth BioCare in?
Hofseth BioCare's product category is Nutraceutical Ingredients. Its primary akta.pro industry code is CRADAFAF, Functional & Veterinary Diet Pet Food, with a secondary code of CRADAFAH, Natural/Organic & Limited-Ingredient Diets. Its NAICS code is 311111 and its SIC code is 2092.